Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17668316 | 1.00 | HSD11B1 (0.46) | HSD11B1CTSDMEN1KMT2AALDH1A1 | |
| SCHEMBL17668327 | 1.00 | HSD11B1 (0.46) | HSD11B1CTSDMEN1KMT2AALDH1A1 | |
| SCHEMBL17668319 | 1.00 | HSD11B1 (0.46) | HSD11B1CTSDMEN1KMT2AALDH1A1 | |
| SCHEMBL17668330 | 1.00 | HSD11B1 (0.46) | HSD11B1CTSDMEN1KMT2AALDH1A1 | |
| SCHEMBL2833847 | 0.83 | HSD11B1 (0.51) | HSD11B1NPSR1HPGD | |
| SCHEMBL17082729 | 0.73 | HSD11B1 (0.55) | HSD11B1MEN1KMT2AALDH1A1OPRK1 | |
| SCHEMBL6142188 | 0.70 | HSD11B1 (0.41) | HSD11B1ALDH1A1GAAHTTOPRK1 | |
| SCHEMBL29213510 | 0.70 | NPC1 (0.48) | HSD11B1CTSDMEN1KMT2AALDH1A1 | |
| SCHEMBL3370759 | 0.70 | AGER (0.55) | CTSDMEN1KMT2ALMNA | |
| SCHEMBL12057025 | 0.70 | EPHX2 (0.47) | HSD11B1MEN1KMT2AALDH1A1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112370-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | HSD11B1 3437/4885CTSD 3280/4885MEN1 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.